State of the art management of diabetic macular edema

Table 3 Summary of the studies using intravitreal Pegaptanib for treatment of diabetic macular edema

Ref.	Purpose	Study design	Out comes measures	IVP dose	Interval of injection	Naive or refractory /DME	Duration of study	Number of eyes	Treatment regimen	Results
Cunningham et al[81]	IVP for DME	RCT	BCVA and CMT	0.3, 1 and 3 mg	1 mo	Naive	36 wk	172	Group 1 (IVP0.3, n = 44 eyes) 0.3 mg IV pegaptanib (90 μL) [median 5 injections (range 1-6)] Group 2 (IVP1, n = 44 eyes) mg IV pegaptanib (90 μL) [median 6 injections (range 3–6))] Group 3 (IVP3, n = 42 eyes) 3 mg IV pegaptanib (90 μL) (median 6 injections (range 1-6) Group 4 (C, n = 42 eyes): sham injection	BCVA changes (letters) P value IVP0.3 +4.7 0.04 IVP1 +4.7 0.05 IVP3 +1.1 NS C -0.4 CMT changes (μm,) IVP0.3 -68.0 0.02 IVP1 -22.7 NS IVP3 -5.3 NS C +3.7
Sultan et al[83]	IVP for DME	RCT	BCVA and CMT	0.3 mg	6 wk	Naive	2 yr	260	Group 1 (IVP, n = 133 eyes): 0.3 mg IV pegaptanib Group 2 (C, n = 127 eyes) sham injection	BCVA changes (letters) P value IVP +5.2 < 0.05 C +1.2 CMT (OCT): Decrease in CMT IVP ≥ 25%: 31.7% NS ≥ 50%: 14.6% NS C ≥ 25%: 23.7% ≥ 50%: 11.9%

DME: Diabetic macular edema; BCVA: Best corrected visual acuity; CMT: Central macular thickness; IVP: Intravitreal pegaptanib.